<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084380</url>
  </required_header>
  <id_info>
    <org_study_id>GPC3CAR</org_study_id>
    <nct_id>NCT03084380</nct_id>
  </id_info>
  <brief_title>Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3&#xD;
      scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating&#xD;
      patients with GPC3-positive advanced hepatocellular carcinoma (HCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. To evaluate the safety of intravenous administration of the anti-GPC3 CAR-T cells in&#xD;
           patients with HCC or lung squamous cell carcinoma&#xD;
&#xD;
        2. To access the safety of anti-GPC3 CAR-T cells in HCC patients through catheter injection&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To evaluate the efficacy of anti-GPC3 CAR-T cells in patients with advanced HCC or lung&#xD;
           squamous cell carcinoma&#xD;
&#xD;
        2. To monitor the serum cytokine and expression level of tumor markers such as AFP, CEA and&#xD;
           GPC3&#xD;
&#xD;
        3. To assess the persistence in peripheral blood and intratumoral infiltration of anti-GPC3&#xD;
           CAR-T cells&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0</measure>
    <time_frame>4 weeks</time_frame>
    <description>Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Overall complete remission rate defined by the standard response criteria</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overall complete remission rate defined by the standard response criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence: Duration of CAR-positive T cells in circulation</measure>
    <time_frame>6 months</time_frame>
    <description>Duration of CAR-positive T cells in circulation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>anti-GPC3 CAR-T</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter arterial chemoembolization (TACE) combine with GPC3-CART infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs</intervention_name>
    <description>transcatheter arterial chemoembolization + CAR-T infusion</description>
    <arm_group_label>anti-GPC3 CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine will be administered at dose of 25mg/m2/d</description>
    <arm_group_label>anti-GPC3 CAR-T</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered</description>
    <arm_group_label>anti-GPC3 CAR-T</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected to survive more than 3 months&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Immunohistochemistry was confirmed to be GPC3 positive hepatocellular carcinoma&#xD;
&#xD;
          -  Patients with no ability to receive TACE combined with sorafenib&#xD;
&#xD;
          -  WBC&gt;3.5×1e+9/L,Hb&gt;90g/L,PLT&gt;75×1e+9/L&#xD;
&#xD;
          -  HBV DNA copy number less than 100/ml&#xD;
&#xD;
          -  ALT≤5ULN, AST≤5ULN, TB≤1.5ULN, ALB≥35g/L&#xD;
&#xD;
          -  Understand this test and have signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hepatic encephalopathy, autoimmune diseases, or any uncontrolled active disease that&#xD;
             hinders participation in the trial&#xD;
&#xD;
          -  Decompensated liver cirrhosis, liver function Child-pugh C grade&#xD;
&#xD;
          -  Portal vein tumor thrombus, arterial portal fistula, hepatic arteriovenous&#xD;
&#xD;
          -  Long-term use of immunosuppressive agents after organ transplantation&#xD;
&#xD;
          -  Screening indicated that the target cell transfection rate was less than 30%&#xD;
&#xD;
          -  Invasive pulmonary embolism, deep venous thrombosis, or other major arterial / venous&#xD;
             thromboembolic events occurred 30 days or 30 days prior to randomization&#xD;
&#xD;
          -  Subjects had an active or uncontrollable infection requiring systemic therapy 14 days&#xD;
             or 14 days prior to randomization&#xD;
&#xD;
          -  Pregnant or lactating subjects&#xD;
&#xD;
          -  In the opinion of the investigator, the presence of a medical history or a history of&#xD;
             mental state may increase the number of subjects associated with the risk factors&#xD;
             associated with the study or study drug administration&#xD;
&#xD;
          -  Subjects who have signed a written consent or who are in compliance with the study&#xD;
             procedure; or who are unwilling or unable to comply with the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Oncology, Xinqiao Hospital</name>
      <address>
        <city>ChongQing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>March 5, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>March 17, 2017</last_update_submitted>
  <last_update_submitted_qc>March 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Qingzhu Jia, M.D.</investigator_full_name>
    <investigator_title>Secretary of research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

